კლინიკური კვლევები

1. Clinical Evaluation of the Panbio™COVID-19/ Flu A&B Rapid Panel. .                                Sponsor: Abbott Rapid Diagnostics Jena GmbH, Start: 01.11.2021                                         Kakha Nadaraia – Principal Investigator (PI)

 

2. A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (AMUC2023)

SPONSOR: Bausch Health Americas, Inc.  Start: 09.2021 Kakha Nadaraia – Subinvestigator   

3. Alfapump® DSR Feasibility Study in Subjects with Persistent Congestion Due to Heart Failure, Resistant to Loop Diuretic Treatment (SAHARA)

Sponsor: Sequana Medical N.V.    Start: 05.2021 Zurab Klimiashvili – Principal Investigator (PI), Tamar Shengelia – Study Coordinator  

4. A Randomized, Placebo-Controlled, Double-blind 52 week Study to Assess the Efficacy and safety of etrazimod in subjects With Moderately active Ulcerative Colitis

Sponsor: Arena Pharmaceuticals,  Start: 19.04.2021 Kakha Nadaraia – Subinvestigator  

5. A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease (CULTIVATE),

Sponsor: Arena Pharmaceuticals, Start: 12.02.2020 Kakha Nadaraia – Subinvestigator  

6. A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel-Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System Inhibitor (Raasi) Medications for the Treatment of Heart Failure (DIAMOND)

Sponsor:  Vifor Pharma, Inc. Collaborator: Syneos Health, LLC, Start: 25.04.2019 Kakha Nadaraia – Study Coordinator and Subinvestigator  

7. Induction Study #1 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease

Sponsor: Celgene,   Start: 27.02.2018 Kakha Nadaraia – Subinvestigator  

8. Induction Study #2 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease

Sponsor: Celgene,   Start: 07.03.2018 Kakha Nadaraia – Subinvestigator  

9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

Sponsor: Celgene,   Start: 27.06.2018 Kakha Nadaraia – Subinvestigator  

10. A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease

Sponsor: Celgene, Start: 22.08.2018 Kakha Nadaraia – Subinvestigator  

11. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric  Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency (HEART-FID)

Sponsor: American Regents inc.  Start: 03.2017 Zurab Klimiashvili – Principal Investigator (PI)  

12. A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Sponsor: Celgene,  Start: 02.12. 2015 Kakha Nadaraia – Cardiologist